Breaking News Instant updates and real-time market news.

GNCA

Genocea

$2.38 /

-0.11 (-4.42%)

09:11
06/04/21
06/04
09:11
06/04/21
09:11

Genocea presents long-term results from GEN-009 Phase 1 trial

Genocea Biosciences presents updated immunogenicity and clinical response data from the GEN-009 Phase 1 trial that continue to validate the company's unique and differentiated approach to identifying clinically meaningful immunotherapy targets through the proprietary ATLAS selection process. Data on the neoantigen vaccine combined with PD-1 inhibition in advanced solid tumors will be shared by Maura Gillison, M.D., Ph.D., Lead Investigator, MD Anderson Cancer Center, during a poster presentation at the virtual 2021 American Society of Clinical Oncology Annual Meeting from June 4-8, 2021. The poster is available for on-demand viewing on the ASCO website and also posted to the Scientific Resources section of the Genocea website here. Long-term results demonstrate that GEN-009 continues to generate broad immune responses against neoantigens that can lead to sustained clinical responses. In Part A of the study, designed to measure safety and immunogenicity only, eight patients with no measurable disease were vaccinated with GEN-009 as a monotherapy. Six of the eight patients continue without recurrence with a median follow up of 25 months post start of the vaccination. Notably, as previously reported, GEN-009 elicited T cell immune responses to 99% of the ATLAS-selected neoantigens, the highest seen across neoantigen vaccine programs. In Part B, patients were enrolled at the initiation of a PD-1 checkpoint inhibitor-based standard of care regimen for advanced or metastatic disease; patients who were controlled on SOC and did not require alternate therapy are labeled CPI-sensitive, patients who required alternate therapy before vaccination are labeled CPI-refractory. Of the nine CPI-sensitive patients, the latest data show four patients experienced novel reduction in tumor volume post-GEN-009 dosing and achieved independent RECIST responses after vaccination, including three partial responses and one complete response. This is an increase from the two PRs and one CR previously reported at SITC 2020. The remaining five CPI-sensitive patients all achieved disease stabilization. Across the CPI-sensitive cohort, the median duration without disease progression after initial GEN-009 vaccination was 15 months. Of the seven CPI-refractory patients, two achieved stable disease after initial GEN-009 vaccination for up to 10 months. GEN-009 has been well tolerated with only mild adverse events associated with the vaccine adjuvant. Expanded immunogenicity data from Part B of the study revealed that vaccine-specific T cell responses were detected ex vivo after the first dose of the vaccine and continued to rise with each subsequent dose. Vaccine-specific T cell responses remained significantly elevated over baseline and post-CPI, pre-vaccine timepoints for at least 6 months, showing persistence of the vaccine response. CPI-sensitive subjects had a greater number of neoantigens identified with ATLAS at baseline compared with patients in the CPI-refractory cohort, and also had evidence of epitope spread for CD8+ T cells post-dosing. Additionally, the magnitude of CD4+ T cell responses were greater for the CPI-refractory than CPI-sensitive subjects, despite a reduced proportion of peptides to which CD4+ T cell responses were measured, suggesting that the breadth and not the magnitude of response could be associated with favorable outcomes.

  • 24

    Jun

GNCA Genocea
$2.38 /

-0.11 (-4.42%)

07/30/20 Stifel
Genocea '009 efficacy boding well for more substantial update ahead, says Stifel
07/27/20 Stifel
Stifel recommends Genocea shares ahead of first look at GEN-009 efficacy
07/23/20 H.C. Wainwright
Genocea price target lowered to $9 from $32 at H.C. Wainwright

TODAY'S FREE FLY STORIES

Hot Stocks
Corvus Gold announces additional results from Mother Lode program » 07:25
06/24/21
06/24
07:25
06/24/21
07:25
KOR

Corvus Gold

$2.68 /

+0.02 (+0.75%)

Corvus Gold announces it…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KOR Corvus Gold
$2.68 /

+0.02 (+0.75%)

KOR Corvus Gold
$2.68 /

+0.02 (+0.75%)

04/15/21 BMO Capital
Corvus Gold initiated with an Outperform at BMO Capital
Recommendations
Winnebago price target lowered to $86 from $94 at Wedbush » 07:24
06/24/21
06/24
07:24
06/24/21
07:24
WGO

Winnebago

$65.98 /

-0.825 (-1.23%)

Wedbush analyst James…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WGO Winnebago
$65.98 /

-0.825 (-1.23%)

WGO Winnebago
$65.98 /

-0.825 (-1.23%)

06:35 Today Baird
Winnebago elevated to bullish Fresh Pick at Baird
06/17/21 Northcoast
Northcoast downgrades three RV makers to Neutral following industry checks
06/17/21 Northcoast
Winnebago downgraded to Neutral from Buy at Northcoast
05/03/21 Citi
Winnebago price target raised to $93 from $73 at Citi
WGO Winnebago
$65.98 /

-0.825 (-1.23%)

WGO Winnebago
$65.98 /

-0.825 (-1.23%)

Hot Stocks
4D Molecular announces expected upcoming milestones » 07:23
06/24/21
06/24
07:23
06/24/21
07:23
FDMT

4D Molecular

$24.81 /

+0.91 (+3.81%)

4D-125: Initial biologic…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FDMT 4D Molecular
$24.81 /

+0.91 (+3.81%)

FDMT 4D Molecular
$24.81 /

+0.91 (+3.81%)

01/05/21 Evercore ISI
4D Molecular initiated with an Outperform at Evercore ISI
01/05/21 BofA
4D Molecular initiated with a Buy at BofA
01/05/21 Goldman Sachs
4D Molecular initiated with a Neutral at Goldman Sachs
  • 11
    Dec
FDMT 4D Molecular
$24.81 /

+0.91 (+3.81%)

Hot Stocks
4D Molecular announces initial safety data for 4D-110, 4D-125 » 07:23
06/24/21
06/24
07:23
06/24/21
07:23
FDMT

4D Molecular

$24.81 /

+0.91 (+3.81%)

4D Molecular Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FDMT 4D Molecular
$24.81 /

+0.91 (+3.81%)

FDMT 4D Molecular
$24.81 /

+0.91 (+3.81%)

01/05/21 Evercore ISI
4D Molecular initiated with an Outperform at Evercore ISI
01/05/21 BofA
4D Molecular initiated with a Buy at BofA
01/05/21 Goldman Sachs
4D Molecular initiated with a Neutral at Goldman Sachs
  • 11
    Dec
FDMT 4D Molecular
$24.81 /

+0.91 (+3.81%)

Hot Stocks
Eli Lilly jumps on expedited plans for Alzheimer's drug, Biogen falls » 07:22
06/24/21
06/24
07:22
06/24/21
07:22
LLY

Eli Lilly

$217.08 /

-4.51 (-2.04%)

, BIIB

Biogen

$371.82 /

-2.77 (-0.74%)

Eli Lilly (LLY) announced…

Eli Lilly (LLY) announced that the Food and Drug Administration granted Breakthrough Therapy designation for donanemab, its investigational antibody therapy for Alzheimer's disease. Lilly intends to submit a biologics license application for donanemab under the accelerated approval pathway later this year based on data from TRAILBLAZER-ALZ. The safety, tolerability and efficacy of donanemab are also being evaluated in the ongoing Phase 3 study TRAILBLAZER-ALZ 2, the company said in a statement. The Phase 2 trial, TRAILBLAZER-ALZ, studied the efficacy and safety of donanemab in patients with early, symptomatic Alzheimer's. Shares of Eli Lilly are up 9%, or $18.50, to $235.60 following the news. Shares of Biogen (BIIB), who recently received FDA approval for its Alzheimer's treatment, are down 6% to $350.02 in premarket trading.

ShowHide Related Items >><<
LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

BIIB Biogen
$371.82 /

-2.77 (-0.74%)

LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

06/15/21 JPMorgan
Eli Lilly price target raised to $260 from $240 at JPMorgan
06/14/21 Goldman Sachs
Eli Lilly price target raised to $270 from $252 at Goldman Sachs
06/08/21 Baird
Baird upgrades Biogen to Neutral after 'fatal blow' to bear thesis
06/07/21 BofA
BofA upgrades Biogen to Neutral with $400 price target after Aduhelm approved
BIIB Biogen
$371.82 /

-2.77 (-0.74%)

06/18/21
Fly Intel: Top five analyst upgrades
06/18/21 Jefferies
Jefferies a buyer of Prothena on Biogen's negative Tau disappointment pullback
06/18/21 BofA
BofA upgrades Prothena to Neutral on PRX012 potential following Aduhelm approval
06/18/21 Piper Sandler
Biogen upgraded to Overweight from Neutral at Piper Sandler
LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

BIIB Biogen
$371.82 /

-2.77 (-0.74%)

LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

BIIB Biogen
$371.82 /

-2.77 (-0.74%)

LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

BIIB Biogen
$371.82 /

-2.77 (-0.74%)

LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

BIIB Biogen
$371.82 /

-2.77 (-0.74%)

Hot Stocks
Aileron Therapeutics set to join Russell Microcap Index » 07:21
06/24/21
06/24
07:21
06/24/21
07:21
ALRN

Aileron Therapeutics

$1.28 /

+0.04 (+3.23%)

Aileron Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ALRN Aileron Therapeutics
$1.28 /

+0.04 (+3.23%)

ALRN Aileron Therapeutics
$1.28 /

+0.04 (+3.23%)

Initiation
Truist starts Taysha Gene Therapies at Buy on potential de-risking events » 07:21
06/24/21
06/24
07:21
06/24/21
07:21
TSHA

Taysha Gene Therapies

$25.25 /

+0.07 (+0.28%)

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TSHA Taysha Gene Therapies
$25.25 /

+0.07 (+0.28%)

TSHA Taysha Gene Therapies
$25.25 /

+0.07 (+0.28%)

06:12 Today Truist
Taysha Gene Therapies initiated with a Buy at Truist
06/14/21 BTIG
Taysha Gene Therapies initiated with a Buy at BTIG
06/09/21 Wedbush
Taysha Gene Therapies initiated with an Outperform at Wedbush
06/08/21 JMP Securities
Taysha Gene Therapies initiated with an Outperform at JMP Securities
TSHA Taysha Gene Therapies
$25.25 /

+0.07 (+0.28%)

  • 24
    Sep
Hot Stocks
Vectivbio receives FDA orphan drug designation for apraglutide » 07:21
06/24/21
06/24
07:21
06/24/21
07:21
VECT

Vectivbio

$12.64 /

-1.26 (-9.06%)

VectivBio announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VECT Vectivbio
$12.64 /

-1.26 (-9.06%)

VECT Vectivbio
$12.64 /

-1.26 (-9.06%)

05/04/21 SVB Leerink
SVB Leerink bullish on Vectivbio, initiates with an Outperform
05/04/21 SVB Leerink
Vectivbio initiated with an Outperform at SVB Leerink
05/04/21 BofA
Vectivbio initiated with a Buy at BofA
05/04/21 Credit Suisse
Vectivbio initiated with an Outperform at Credit Suisse
  • 09
    Apr
VECT Vectivbio
$12.64 /

-1.26 (-9.06%)

Hot Stocks
4D Molecular anounces rare disease ophthalmology product candidate update » 07:20
06/24/21
06/24
07:20
06/24/21
07:20
FDMT

4D Molecular

$24.81 /

+0.91 (+3.81%)

"We believe the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FDMT 4D Molecular
$24.81 /

+0.91 (+3.81%)

FDMT 4D Molecular
$24.81 /

+0.91 (+3.81%)

01/05/21 Evercore ISI
4D Molecular initiated with an Outperform at Evercore ISI
01/05/21 BofA
4D Molecular initiated with a Buy at BofA
01/05/21 Goldman Sachs
4D Molecular initiated with a Neutral at Goldman Sachs
  • 11
    Dec
FDMT 4D Molecular
$24.81 /

+0.91 (+3.81%)

Hot Stocks
Werewolf Therapeutics set to join Russell 2000 Index » 07:19
06/24/21
06/24
07:19
06/24/21
07:19
HOWL

Werewolf Therapeutics

$15.09 /

+0.39 (+2.65%)

Werewolf Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HOWL Werewolf Therapeutics
$15.09 /

+0.39 (+2.65%)

HOWL Werewolf Therapeutics
$15.09 /

+0.39 (+2.65%)

05/25/21
Fly Intel: Top five analyst initiations
05/25/21 SVB Leerink
SVB Leerink bullish on Werewolf Therapeutics, initiates with an Outperform
05/25/21 SVB Leerink
Werewolf Therapeutics initiated with an Outperform at SVB Leerink
05/25/21 Evercore ISI
Werewolf Therapeutics initiated with an Outperform at Evercore ISI
HOWL Werewolf Therapeutics
$15.09 /

+0.39 (+2.65%)

  • 30
    Apr
HOWL Werewolf Therapeutics
$15.09 /

+0.39 (+2.65%)

Hot Stocks
Enthusiast Gaming closes acquisition of Tabwire for $11M in cash, stock » 07:18
06/24/21
06/24
07:18
06/24/21
07:18
EGLX

Enthusiast Gaming

$5.75 /

+0.405 (+7.58%)

Enthusiast Gaming…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
EGLX Enthusiast Gaming
$5.75 /

+0.405 (+7.58%)

EGLX Enthusiast Gaming
$5.75 /

+0.405 (+7.58%)

06/23/21 H.C. Wainwright
Enthusiast Gaming initiated with a Buy at H.C. Wainwright
  • 11
    Jun
EGLX Enthusiast Gaming
$5.75 /

+0.405 (+7.58%)

Initiation
Vaxart initiated with a Buy at Jefferies » 07:18
06/24/21
06/24
07:18
06/24/21
07:18
VXRT

Vaxart

$7.84 /

-0.05 (-0.63%)

Jefferies analyst Kelechi…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VXRT Vaxart
$7.84 /

-0.05 (-0.63%)

VXRT Vaxart
$7.84 /

-0.05 (-0.63%)

06/11/21
Fly Intel: Top five analyst initiations
06/11/21 Piper Sandler
Vaxart initiated with an Overweight at Piper Sandler
03/04/21 B. Riley Securities
Vaxart price target lowered to $13 from $16 at B. Riley Securities
11/18/20 B. Riley Securities
Vaxart price target lowered to $16 from $22 at B. Riley Securities
VXRT Vaxart
$7.84 /

-0.05 (-0.63%)

VXRT Vaxart
$7.84 /

-0.05 (-0.63%)

VXRT Vaxart
$7.84 /

-0.05 (-0.63%)

VXRT Vaxart
$7.84 /

-0.05 (-0.63%)

Hot Stocks
4D Molecular announces termination of Roche collaboration, license agreement » 07:18
06/24/21
06/24
07:18
06/24/21
07:18
FDMT

4D Molecular

$24.81 /

+0.91 (+3.81%)

, RHHBY

Roche

$46.13 /

-0.67 (-1.43%)

Roche (RHHBY) requested…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FDMT 4D Molecular
$24.81 /

+0.91 (+3.81%)

RHHBY Roche
$46.13 /

-0.67 (-1.43%)

FDMT 4D Molecular
$24.81 /

+0.91 (+3.81%)

01/05/21 Evercore ISI
4D Molecular initiated with an Outperform at Evercore ISI
01/05/21 BofA
4D Molecular initiated with a Buy at BofA
01/05/21 Goldman Sachs
4D Molecular initiated with a Neutral at Goldman Sachs
RHHBY Roche
$46.13 /

-0.67 (-1.43%)

06/14/21 Berenberg
Roche price target raised to CHF 340 from CHF 320 at Berenberg
06/10/21 Morgan Stanley
Roche price target raised to CHF 370 from CHF 345 at Morgan Stanley
06/07/21 BofA
BofA upgrades Biogen to Neutral with $400 price target after Aduhelm approved
06/02/21 Societe Generale
Roche downgraded to Hold from Buy at Societe Generale
RHHBY Roche
$46.13 /

-0.67 (-1.43%)

  • 11
    Dec
RHHBY Roche
$46.13 /

-0.67 (-1.43%)

RHHBY Roche
$46.13 /

-0.67 (-1.43%)

FDMT 4D Molecular
$24.81 /

+0.91 (+3.81%)

Hot Stocks
Corvus Gold announces additional results from Mother Lode program » 07:17
06/24/21
06/24
07:17
06/24/21
07:17
KOR

Corvus Gold

$2.68 /

+0.02 (+0.75%)

Corvus Gold announces it…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KOR Corvus Gold
$2.68 /

+0.02 (+0.75%)

KOR Corvus Gold
$2.68 /

+0.02 (+0.75%)

04/15/21 BMO Capital
Corvus Gold initiated with an Outperform at BMO Capital
Hot Stocks
Bio-Techne and Catamaran Bio expand collaboration for CAR-NK cell therapies » 07:16
06/24/21
06/24
07:16
06/24/21
07:16
TECH

Bio-Techne

$444.01 /

+3.1 (+0.70%)

Bio-Techne and Catamaran…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TECH Bio-Techne
$444.01 /

+3.1 (+0.70%)

TECH Bio-Techne
$444.01 /

+3.1 (+0.70%)

06/18/21 Argus
Bio-Techne price target raised to $490 from $440 at Argus
05/07/21 Baird
Bio-Techne price target raised to $430 from $410 at Baird
03/08/21 Stephens
Bio-Techne upgraded to Overweight from Equal Weight at Stephens
02/23/21 Stifel
Stifel upgrades Bio-Techne to Buy, sees strong case for outperformance
TECH Bio-Techne
$444.01 /

+3.1 (+0.70%)

Hot Stocks
FDA accepts Alnylam NDA for vutrisiran, an investigational RNAi therapeutic » 07:15
06/24/21
06/24
07:15
06/24/21
07:15
ALNY

Alnylam

$174.69 /

+1.64 (+0.95%)

Alnylam Pharmaceuticals …

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ALNY Alnylam
$174.69 /

+1.64 (+0.95%)

ALNY Alnylam
$174.69 /

+1.64 (+0.95%)

06/11/21 BMO Capital
Alnylam coverage transferred at BMO Capital
02/22/21 Guggenheim
Alnylam downgraded to Neutral from Buy at Guggenheim
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 Barclays
Alnylam price target raised to $196 from $162 at Barclays
ALNY Alnylam
$174.69 /

+1.64 (+0.95%)

Hot Stocks
Applied Genetic reports 12-month data from ongoing Phase 1/2 trial of ACHM A3 » 07:15
06/24/21
06/24
07:15
06/24/21
07:15
AGTC

Applied Genetic

$4.17 /

+0.02 (+0.48%)

Applied Genetic…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AGTC Applied Genetic
$4.17 /

+0.02 (+0.48%)

AGTC Applied Genetic
$4.17 /

+0.02 (+0.48%)

06/14/21 BTIG
Applied Genetic initiated with a Buy at BTIG
04/19/21 Roth Capital
Roth Capital 'bullish' on Applied Genetic's technology, pipeline outlook
04/13/21 Roth Capital
Roth Capital sees Applied Genetic's XLRS licensing as vote of confidence
03/01/21 Stifel
Applied Genetic initiated with a Buy at Stifel
AGTC Applied Genetic
$4.17 /

+0.02 (+0.48%)

  • 28
    Jan
AGTC Applied Genetic
$4.17 /

+0.02 (+0.48%)

Hot Stocks
Applied Genetic reports 12-month data from ongoing Phase 1/2 trial of ACHM B3 » 07:15
06/24/21
06/24
07:15
06/24/21
07:15
AGTC

Applied Genetic

$4.17 /

+0.02 (+0.48%)

Applied Genetic reported…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AGTC Applied Genetic
$4.17 /

+0.02 (+0.48%)

AGTC Applied Genetic
$4.17 /

+0.02 (+0.48%)

06/14/21 BTIG
Applied Genetic initiated with a Buy at BTIG
04/19/21 Roth Capital
Roth Capital 'bullish' on Applied Genetic's technology, pipeline outlook
04/13/21 Roth Capital
Roth Capital sees Applied Genetic's XLRS licensing as vote of confidence
03/01/21 Stifel
Applied Genetic initiated with a Buy at Stifel
AGTC Applied Genetic
$4.17 /

+0.02 (+0.48%)

  • 28
    Jan
AGTC Applied Genetic
$4.17 /

+0.02 (+0.48%)

Hot Stocks
Darden reports Q4 blended same-restaurant sales up 90.4% y/y » 07:15
06/24/21
06/24
07:15
06/24/21
07:15
DRI

Darden

$135.42 /

-0.17 (-0.13%)

Q4 same-restaurant sales…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DRI Darden
$135.42 /

-0.17 (-0.13%)

DRI Darden
$135.42 /

-0.17 (-0.13%)

06/22/21 Baird
Darden risk/reward remains attractive, says Baird
06/22/21 RBC Capital
Darden price target raised to $162 from $158 at RBC Capital
06/09/21 Truist
Darden price target raised to $170 from $158 at Truist
06/01/21 Barclays
Darden price target lowered to $157 from $164 at Barclays
DRI Darden
$135.42 /

-0.17 (-0.13%)

DRI Darden
$135.42 /

-0.17 (-0.13%)

DRI Darden
$135.42 /

-0.17 (-0.13%)

Hot Stocks
XPO Logistics named official transport partner of Tour de France » 07:14
06/24/21
06/24
07:14
06/24/21
07:14
XPO

XPO Logistics

$148.24 /

+0.46 (+0.31%)

XPO Logistics will take…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
XPO XPO Logistics
$148.24 /

+0.46 (+0.31%)

XPO XPO Logistics
$148.24 /

+0.46 (+0.31%)

06/18/21 Wells Fargo
XPO Logistics price target raised to $183 from $158 at Wells Fargo
06/18/21 Barclays
XPO Logistics price target raised to $180 from $160 at Barclays
06/17/21 Truist
XPO Logistics price target raised to $176 from $160 at Truist
06/10/21 KeyBanc
XPO Logistics price target raised to $175 from $170 at KeyBanc
XPO XPO Logistics
$148.24 /

+0.46 (+0.31%)

XPO XPO Logistics
$148.24 /

+0.46 (+0.31%)

XPO XPO Logistics
$148.24 /

+0.46 (+0.31%)

Recommendations
UBS analyst says GE 'most vaccine-levered stock' in coverage » 07:14
06/24/21
06/24
07:14
06/24/21
07:14
GE

General Electric

$12.95 /

-0.065 (-0.50%)

UBS analyst Markus…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GE General Electric
$12.95 /

-0.065 (-0.50%)

GE General Electric
$12.95 /

-0.065 (-0.50%)

05/19/21 Barclays
Barclays ups target on top pick GE to $16 on improving aviation data
05/14/21 Citi
General Electric reinstated with a Buy at Citi
04/29/21 Stephens
AerCap named a Best Idea at Stephens
04/28/21 Deutsche Bank
General Electric price target raised to $15 from $14 at Deutsche Bank
GE General Electric
$12.95 /

-0.065 (-0.50%)

GE General Electric
$12.95 /

-0.065 (-0.50%)

GE General Electric
$12.95 /

-0.065 (-0.50%)

GE General Electric
$12.95 /

-0.065 (-0.50%)

Initiation
Inovio initiated with a Hold at Jefferies » 07:13
06/24/21
06/24
07:13
06/24/21
07:13
INO

Inovio

$8.68 /

-0.05 (-0.57%)

Jefferies analyst Kelechi…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
INO Inovio
$8.68 /

-0.05 (-0.57%)

INO Inovio
$8.68 /

-0.05 (-0.57%)

05/10/21 Piper Sandler
Inovio price target lowered to $6 from $7 at Piper Sandler
05/10/21 Piper Sandler
Inovio Phase 2 data for INO-4800 'lackluster,' says Piper Sandler
04/26/21 B. Riley
B. Riley reiterates Buy on Novavax, Sell on Arcturus amid vaccine developments
04/23/21 Oppenheimer
Oppenheimer still bullish on Inovio after U.S. discontinues trial funding
INO Inovio
$8.68 /

-0.05 (-0.57%)

  • 21
    Jan
INO Inovio
$8.68 /

-0.05 (-0.57%)

INO Inovio
$8.68 /

-0.05 (-0.57%)

Recommendations
Aspen Group a good entry point following retreat from highs, says Canaccord » 07:12
06/24/21
06/24
07:12
06/24/21
07:12
ASPU

Aspen Group

$7.00 /

+1.04 (+17.45%)

Canaccord analyst Austin…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ASPU Aspen Group
$7.00 /

+1.04 (+17.45%)

ASPU Aspen Group
$7.00 /

+1.04 (+17.45%)

05/18/21 Roth Capital
Aspen Group risk/reward 'highly favorable,' says Roth Capital
03/01/21 Craig-Hallum
Aspen pullback on CFO departure presents buying opportunity, says Craig-Hallum
01/06/21 Roth Capital
Arizona nursing school results positive for Aspen, says Roth Capital
09/22/20 B. Riley FBR
Aspen Group price target raised to $15 from $14 at B. Riley FBR
ASPU Aspen Group
$7.00 /

+1.04 (+17.45%)

ASPU Aspen Group
$7.00 /

+1.04 (+17.45%)

ASPU Aspen Group
$7.00 /

+1.04 (+17.45%)

Hot Stocks
Navidea unit MT wins case against Michael Goldberg for breach of fiduciary duty » 07:12
06/24/21
06/24
07:12
06/24/21
07:12
NAVB

Navidea

$1.93 /

+0.15 (+8.43%)

Navidea…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NAVB Navidea
$1.93 /

+0.15 (+8.43%)

NAVB Navidea
$1.93 /

+0.15 (+8.43%)

08/17/20 H.C. Wainwright
Navidea price target raised to $8 from $6 at H.C. Wainwright
Hot Stocks
Karyopharm expands royalty agreement with HealthCare Royalty for up to $100M » 07:12
06/24/21
06/24
07:12
06/24/21
07:12
KPTI

Karyopharm

$10.34 /

-0.09 (-0.86%)

Karyopharm has expanded…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
KPTI Karyopharm
$10.34 /

-0.09 (-0.86%)

KPTI Karyopharm
$10.34 /

-0.09 (-0.86%)

05/04/21 Baird
Karyopharm price target lowered to $30 from $35 at Baird
05/04/21 RBC Capital
Karyopharm price target lowered to $19 from $24 at RBC Capital
02/12/21 Barclays
Karyopharm price target lowered to $22 from $26 at Barclays
02/01/21 Barclays
Karyopharm price target lowered to $26 from $31 at Barclays
KPTI Karyopharm
$10.34 /

-0.09 (-0.86%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.